Paul A Vanderlaan - JoVE Visualize

Showing results (61-70 of 121) with videos related to

Pageof 13

Sort By:

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.

Translational Lung Cancer Research|August 14, 2023

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugatesDaniel Sentana-Lledo, Emmeline Academia, Hollis Viray, et al.

JTO Clinical and Research Reports|March 30, 2023

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor-Responsive Lung Cancer Driver OncogeneZachary R Schoepflin, Emmeline Academia, Soravis A Osataphan, et al.

Journal of Bronchology & Interventional Pulmonology|February 27, 2020

Thermoablative Techniques for Excessive Central Airway Collapse: An Ex Vivo Pilot Study on Sheep Tracheal TissueAndres de Lima, Barbara Vidal, Fayez Kheir, et al.

World Neurosurgery|July 22, 2018

Histopathological Demonstration of Subacute Endothelialization Following Aneurysm Retreatment with the Pipeline Embolization DeviceKrishnan Ravindran, Marcello DiStasio, Roger Laham, et al.

Cancer Treatment Communications|January 24, 2017

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practiceDeepa Rangachari, Lauren Drake, Mark S Huberman, et al.

JTO Clinical and Research Reports|January 17, 2024

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase InhibitorsIkei S Kobayashi, William Shaffer, Hollis Viray, et al.

Respiratory Medicine|November 30, 2024

A quantitative method for assessing treatment-related changes within the airway mucosa in patients with chronic bronchitisWilliam S Krimsky, Paul A VanderLaan, Jeffrey S Iding, et al.

Clinical Lung Cancer|July 7, 2016

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-ReviewYuri Sheikine, Deepa Rangachari, Danielle C McDonald, et al.

The American Journal of Pathology|February 27, 2007

Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosisPaul A VanderLaan, Catherine A Reardon, Yuval Sagiv, et al.

Pageof 13

Showing results (61-70 of 121) with videos related to

Sort By:

Pageof 13

Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 21, 2017

Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≥50% Expression in Lung AdenocarcinomaDeepa Rangachari, Paul A VanderLaan, Meghan Shea, et al.

Translational Lung Cancer Research|August 14, 2023

EGFR exon 20 insertion mutations and ERBB2 mutations in lung cancer: a narrative review on approved targeted therapies from oral kinase inhibitors to antibody-drug conjugatesDaniel Sentana-Lledo, Emmeline Academia, Hollis Viray, et al.

JTO Clinical and Research Reports|March 30, 2023

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor-Responsive Lung Cancer Driver OncogeneZachary R Schoepflin, Emmeline Academia, Soravis A Osataphan, et al.

Journal of Bronchology & Interventional Pulmonology|February 27, 2020

Thermoablative Techniques for Excessive Central Airway Collapse: An Ex Vivo Pilot Study on Sheep Tracheal TissueAndres de Lima, Barbara Vidal, Fayez Kheir, et al.

World Neurosurgery|July 22, 2018

Histopathological Demonstration of Subacute Endothelialization Following Aneurysm Retreatment with the Pipeline Embolization DeviceKrishnan Ravindran, Marcello DiStasio, Roger Laham, et al.

Cancer Treatment Communications|January 24, 2017

Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practiceDeepa Rangachari, Lauren Drake, Mark S Huberman, et al.

JTO Clinical and Research Reports|January 17, 2024

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase InhibitorsIkei S Kobayashi, William Shaffer, Hollis Viray, et al.

Respiratory Medicine|November 30, 2024

A quantitative method for assessing treatment-related changes within the airway mucosa in patients with chronic bronchitisWilliam S Krimsky, Paul A VanderLaan, Jeffrey S Iding, et al.

Clinical Lung Cancer|July 7, 2016

EGFR Testing in Advanced Non-Small-Cell Lung Cancer, A Mini-ReviewYuri Sheikine, Deepa Rangachari, Danielle C McDonald, et al.

The American Journal of Pathology|February 27, 2007

Characterization of the natural killer T-cell response in an adoptive transfer model of atherosclerosisPaul A VanderLaan, Catherine A Reardon, Yuval Sagiv, et al.

Pageof 13